Bokus

Sadia Nawab – författare

Visar alla böcker från författaren Sadia Nawab. Handla med fri frakt och snabb leverans.

3 produkter

  1. Aman Chandra Kaushik, Aamir Mehmood, Dongqing Wei, Sadia Nawab, Shakti Sahi, Ajay Kumar - Cheminformatics and Bioinformatics at the Interface with Systems Biology, Inbunden. Tillgänglighet: Lägg i varukorg

    Cheminformatics and Bioinformatics at the Interface with Systems Biology

    Bridging Chemistry and Medicine

    Av Aman Chandra Kaushik, Aamir Mehmood m. fl.

    Inbunden, 2023

    2913 kr

    Lägg i varukorg

    The cost of drug development is increasing, and investment returns are decreasing. The number of drugs approved by FDA is in decline in terms of the number of new molecular entities (NMEs). Amongst the reasons noted for this are the adverse side effects and reduced efficiency of many of the …

  2. Ajay Kumar, Shakti Sahi, Sadia Nawab, Dongqing Wei, Aamir Mehmood, Aman Chandra Kaushik - Cheminformatics and Bioinformatics at the Interface with Systems Biology, E-bok. Tillgänglighet: Lägg i varukorg

    Cheminformatics and Bioinformatics at the Interface with Systems Biology

    Bridging Chemistry and Medicine

    Av Ajay Kumar, Shakti Sahi m. fl.

    E-bok, 2023

    2669 kr

    Lägg i varukorg

    The cost of drug development is increasing, and investment returns are decreasing. The number of drugs approved by FDA is in decline in terms of the number of new molecular entities (NMEs). Amongst the reasons noted for this are the adverse side effects and reduced efficiency of many of the …

  3. Ajay Kumar, Shakti Sahi, Sadia Nawab, Dongqing Wei, Aamir Mehmood, Aman Chandra Kaushik - Cheminformatics and Bioinformatics at the Interface with Systems Biology, E-bok. Tillgänglighet: Lägg i varukorg

    Cheminformatics and Bioinformatics at the Interface with Systems Biology

    Bridging Chemistry and Medicine

    Av Ajay Kumar, Shakti Sahi m. fl.

    E-bok, 2023

    2669 kr

    Lägg i varukorg

    The cost of drug development is increasing, and investment returns are decreasing. The number of drugs approved by FDA is in decline in terms of the number of new molecular entities (NMEs). Amongst the reasons noted for this are the adverse side effects and reduced efficiency of many of the …